Conjunctive effects of fibroblast growth factor and glycosaminoglycan on bone metabolism in neonatal bartter syndrome

Pediatric Research

Volumn 45, Issue 5, 1999, Pages 726-732

  Williams, William J ^a   Shoemaker, Lawrence R ^b   Schurman, Scott J ^c   Welch, Thomas R ^d   Bergstrom, William H ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GLYCOSAMINOGLYCAN;

AGED; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; BARTTER SYNDROME; BONE MINERALIZATION; CALCIUM MOBILIZATION; CASE REPORT; CHILD; CONTROLLED STUDY; HORMONAL REGULATION; HUMAN; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

AGED; ANIMALS; BARTTER SYNDROME; BIOLOGICAL ASSAY; CALCIUM; CHILD; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, ION EXCHANGE; FIBROBLAST GROWTH FACTOR 2; GLYCOSAMINOGLYCANS; HUMANS; MALE; RATS; REFERENCE VALUES; SKULL;

EID: 0032953407     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1203/00006450-199905010-00020     Document Type: Article

References (32)

1. Seyberth HW, Rascher W, Schweer H, Kühl PG, Mehls O, Schärer K 1985 Congenital hypokalemia with hypercalciuria in preterm infants: a hyperprostaglandinuric tubular syndrome different from Bartter syndrome. J Pediatr 107:694-701
2. de Rovetto CR, Welch TR, Hug G, Clark KE, Bergstrom W 1989 Hypercalciuria with Bartter syndrome: evidence for an abnormality of vitamin D metabolism. J Pediatr 115:397-404
3. Shoemaker L, Welch TR, Bergstrom W, Abrams SA, Yergey AL, Vieira N 1993 Calcium kinetics in the hyperprostaglandin E syndrome. Pediatr Res 33:92-96
4. Shoemaker LR, Bergstrom W, Ragosta K, Welch TR 1998 Humoral factor in children with hyperprostaglandin E syndrome reduces bone calcium uptake in vitro. Pediatr Nephrol 12:371-376
5. Chowdhury MH, Hamada C, Dempster DW 1992 Effects of heparin on osteoclast activity. J Bone Min Res 7:771-777
6. Shaughnessy SG, Young E, Deschamps P, Hirsh J 1995 The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 86:1368-1373
7. Fuller K, Chambers TJ, Gallagher AC 1991 Heparin augments osteoclasts resorption-stimulating activity in serum. J Cell Physiol 147:208-214
8. Simmons HA, Raisz LG 1991 Effects of acid and basic fibroblast growth factor and heparin on resorption of cultured fetal rat long bones. J Bone Min Res 6:1301-1305
9. Tashjian AH, Voelkel EF, Lazzaro M, Singer FR, Roberts AB, Derynck R, Winkler ME, Levine L 1985 α and β human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvaria. Proc Natl Acad Sci USA 82:4535-4538
10. Shoemaker LR, Bergstrom W, Welch TR, Ragosta K 1995 The role of basic fibroblast growth factor (bFGF) in heparin-induced bone resorption. Pediatr Res 37:79A(abstr)
11. Bergstrom WH 1992 Bone disc bioassay for calciotropic agents. J Bone Min Res 7:S244
12. Ragosta KG, Bergstrom WH, Briggs DB, Brandt B 1996 Protamine and acute depletion of magnesium limit bone response to parathyroid hormone. Anesth Analg 82:29-32
13. Bett IM, Fraser GP 1958 A rapid micro method for determining serum calcium. Biochem J 68:13P
14. Thompson AR, Counts RB 1976 Removal of heparin and protamine from plasma. J Lab Clin Med 88:922-929
15. Yanagishita M, Midura RJ, Hascall VC 1987 Proteoglycans: isolation and purification from tissue cultures. Methods Enzymol 138:279-289
16. Farndale RW, Sayers CA, Barrett AJ 1982 A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res 9:247-248
17. Oohira A, Wight TN, Bornstein P 1983 Sulfated proteoglycans synthesized by vascular endothelial cells in culture. J Biol Chem 258:2014-2021
18. Gaspodarowicz D, Cheng J, Lui GM, Baird A, Böhlent P 1984 Isolation of brain fibroblast growth factor by heparin-Sepharose affinity chromatography: identity with pituitary fibroblast growth factor. Proc Natl Acad Sci USA 81:6963-6967
19. Yayon A, Aviezer D, Safran M, Gross JL, Heldman Y, Cabilly S, Givol D, Katchalski-Katzir E 1993 Isolation of peptides that inhibit binding of basic fibroblast growth factor to its receptor from a random phage-epitope library. Proc Nat Acad Sci USA 90:10643-10647
20. Michelacci YM, Glashan RQ, Schor N 1989 Urinary excretion of glycosaminoglycans in normal and stone forming subjects. Kidney Int 36:1022-1028
21. Bashkin P, Doctrow S, Klagsbrun M, Svahn CM, Folkman J, Vlodavsky I 1989 Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 28:1737-1743
22. Ornitz DM, Yayon A, Flanagan JG, Svahn CM, Levi E, Leder P 1992 Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 12:240-247
23. Ishihara M, Tyrell DJ, Stauber GB, Brown S, Cousens LS, Stack RJ 1993 Preparation of affinity-fractionated, heparin-derived oligosaccharides and their effects on selected biological activities mediated by basic fibroblast growth factor. J Biol Chem 268:4675-4683
24. Tyrrell DJ, Ishihara M, Rao N, Horne A, Kiefer MC, Stauber GB, Lam LH, Stack RJ 1993 Structure and biological activities of a heparin-derived hexasaccharide with high affinity for basic fibroblast growth factor. J Biol Chem 268:4684-4689
25. Maccarana M, Casu B, Lindahl U 1993 Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chem 268:23898-23905
26. Guimond S, Maccarana M, Olwin BB, Lindahl J, Rapraeger AC 1993 Activating and inhibitory sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem 268:23906-23914
27. Ornitz DM, Herr AB, Nilsson M, Westman J, Svahn CM, Waksman G 1995 FGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharides. Science 268:432-435
28. Simon DB, Karet FE, Hamdan JM, Di Pietro A, Sanjad SA, Lifton RP 1996 Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nature Genet 13:183-188
29. +channel, ROMK. Nature Genet 14:152-156
30. International Collaborative Study Group for Barrter-like Syndromes 1997 Mutations in the gene encoding the inwardly-rectifying renal potassium channel, ROMK, cause the antenatal variant of Bartter syndrome: evidence for genetic heterogeneity. Hum Mol Genet 6:17-26
31. Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R, Schurman S, Nayir A, Alpay H, Bakkaloglu A, Rodriguez-Soriano J, Morales JM, Sanjad SA, Taylor CM, Pilz D, Brem A, Trachtman H, Griswold W, Richard GA, John E, Lifton RP 1997 Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nature Genet 17:171-178
32. Schurman SJ, Bergstrom WH, Shoemaker LR, Simon DB 1998 Contrasting phenotypes of children with different Bartter's syndrome (BS) gene defects. Pediatr Res 43:85A(abstr)